ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The San Diego–based biotechnology firm BlossomHill Therapeutics has raised $100 million in series B funding. The company was founded in 2020 by Jean Cui and Peter Li, who had also cofounded Turning Point Therapeutics, now owned by Bristol Myers Squibb. BlossomHill focuses on small-molecule treatments for cancer and autoimmune diseases. The cash comes as the firm moves its first two oncology molecules into Phase 1 clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter